Miami Herald - The U.S. Food and Drug Administration told Miami-based Noven Pharmaceuticals ( NOVN ) it can approve its potential treatment for bipolar disorder, migraines and seizures after receiving additional ''non-clinical'' information. Noven said it expects ...